Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy
Cytometry Part B: Clinical Cytometry · 2023
DOI: 10.1002/cyto.b.22120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cytometry Part B: Clinical Cytometry, 2023. Verfasst von Qi Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
Measurement of minimal/measurable residual disease (MRD) in B‐lymphoblastic leukemia/lymphoma (B‐ALL) has become a routine clinical evaluation tool and remains the strongest predictor of treatment outcome. In recent years, new targeted anti‐CD19 and anti‐CD22 antibody‐based and cellular therapies have revolutionized the treatment of the high‐risk B‐ALL. The new treatments raise challenges for diagnostic flow cytometry, which relies on the presence of specific surface antigens to identify the population of interest. So far, reported flow cytometry‐based assays are developed to either achieve a deeper MRD level or to accommodate the loss of surface antigens post‐target therapies, but not both.
Methods
We developed a single tube flow cytometry assay (14‐color‐16‐parameters). The method was validated using 94 clinical samples as well as spike‐in and replicate experiments.
Results
The assay was well suited for monitoring response to targeted therapies and reached a sensitivity below 10 −5 with acceptable precision (coefficient of variation < 20%), accuracy, and interobserver variability ( κ = 1).
Conclusions
The assay allows for sensitive disease detection of B‐ALL MRD independent of CD19 and CD22 expression and allows uniform analysis of samples regardless of anti‐CD19 and CD22 therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Qi Gao
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Gao, Q., Liu, Y., Aypar, U., Baik, J., Londono, D., Sun, X., Zhang, J., Zhang, Y., & Roshal, M. (2023). Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy. Cytometry Part B: Clinical Cytometry. https://doi.org/10.1002/cyto.b.22120
Vancouver
Gao Q, Liu Y, Aypar U, Baik J, Londono D, Sun X, et al. Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy. Cytometry Part B: Clinical Cytometry. 2023. doi:10.1002/cyto.b.22120
BibTeX
@article{Gao2023,
author = {Gao, Qi and Liu, Ying and Aypar, Umut and Baik, Jeeyeon and Londono, Dory and Sun, Xiaotian and Zhang, Jingping and Zhang, Yanming and Roshal, Mikhail},
title = {Highly sensitive single tube B‐lymphoblastic leukemia/lymphoma minimal/measurable residual disease test robust to surface antigen directed therapy},
journal = {Cytometry Part B: Clinical Cytometry},
year = {2023},
doi = {10.1002/cyto.b.22120}
}
EUVIMED